Conference
Phase I study of NX211 given as an intravenous infusion on days 1, 2 & 3 every 3 weeks in patients (pts) with solid tumors - an NCIC Clinical Trials Group study.
Authors
Gelmon KA; Eisenhauer E; Reyno L; Fisher B; Ayers D; Lee U; Hirte H; D'Aloisio S; Hurak S; Hamilton M
Volume
5
Pagination
pp. 3794S-3794S
Publisher
AMER ASSOC CANCER RESEARCH
Publication Date
November 1, 1999
Conference proceedings
CLINICAL CANCER RESEARCH
ISSN
1078-0432